Search research articles
Contact Us
Filters
Showing results (371-380 of 480) with videos related to
Page
of 48
Sort By:
Trials
|
July 14, 2014
Improving Well-being and Health for People with Dementia (WHELD): study protocol for a randomised controlled trial
Rhiannon Whitaker, Jane Fossey, Clive Ballard, et al.
BMJ (Clinical Research Ed.)
|
February 22, 2005
Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial
Clive Ballard, Marisa Margallo-Lana, Edmund Juszczak, et al.
Nature and Science of Sleep
|
January 15, 2021
Striatal Dopaminergic Deficit and Sleep in Idiopathic Rapid Eye Movement Behaviour Disorder: An Explorative Study
Danielle Wasserman, Dorothea Bindman, Alexander D Nesbitt, et al.
BMC Geriatrics
|
August 4, 2022
Attitudes toward own aging and cognition among individuals living with and without dementia: findings from the IDEAL programme and the PROTECT study
Serena Sabatini, Anthony Martyr, Obioha C Ukoumunne, et al.
Nature Communications
|
May 6, 2026
Alzheimer's Disease blood biomarkers measured through remote capillary sampling correlate with cognition in older adults
Anne Corbett, Millie Sander-Long, Nicholas J Ashton, et al.
Alzheimer'S & Dementia (Amsterdam, Netherlands)
|
October 22, 2020
FLAME: A computerized neuropsychological composite for trials in early dementia
Helen Brooker, Gareth Williams, Adam Hampshire, et al.
Current Alzheimer Research
|
January 11, 2018
(-)-Phenserine and Inhibiting Pre-Programmed Cell Death: In Pursuit of a Novel Intervention for Alzheimer's Disease
Robert E Becker, Nigel H Greig, Debomoy K Lahiri, et al.
Neurobiology of Aging
|
August 9, 2014
Assessment of ZnT3 and PSD95 protein levels in Lewy body dementias and Alzheimer's disease: association with cognitive impairment
David R Whitfield, Julie Vallortigara, Amani Alghamdi, et al.
Alzheimer'S & Dementia (New York, N. Y.)
|
March 1, 2022
Treatment with glucagon-like peptide-1 receptor agonists and incidence of dementia: Data from pooled double-blind randomized controlled trials and nationwide disease and prescription registers
Caroline Holm Nørgaard, Sarah Friedrich, Charlotte Thim Hansen, et al.
Nature Aging
|
December 19, 2025
Repurposing glucagon-like peptide-1 receptor agonists for the treatment of neurodegenerative disorders
Marwan N Sabbagh, Jeffrey L Cummings, Clive Ballard, et al.
Page
of 48
Search research articles
Search
Showing results (371-380 of 480) with videos related to
Sort By:
Page
of 48
Trials
|
July 14, 2014
Improving Well-being and Health for People with Dementia (WHELD): study protocol for a randomised controlled trial
Rhiannon Whitaker, Jane Fossey, Clive Ballard, et al.
BMJ (Clinical Research Ed.)
|
February 22, 2005
Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial
Clive Ballard, Marisa Margallo-Lana, Edmund Juszczak, et al.
Nature and Science of Sleep
|
January 15, 2021
Striatal Dopaminergic Deficit and Sleep in Idiopathic Rapid Eye Movement Behaviour Disorder: An Explorative Study
Danielle Wasserman, Dorothea Bindman, Alexander D Nesbitt, et al.
BMC Geriatrics
|
August 4, 2022
Attitudes toward own aging and cognition among individuals living with and without dementia: findings from the IDEAL programme and the PROTECT study
Serena Sabatini, Anthony Martyr, Obioha C Ukoumunne, et al.
Nature Communications
|
May 6, 2026
Alzheimer's Disease blood biomarkers measured through remote capillary sampling correlate with cognition in older adults
Anne Corbett, Millie Sander-Long, Nicholas J Ashton, et al.
Alzheimer'S & Dementia (Amsterdam, Netherlands)
|
October 22, 2020
FLAME: A computerized neuropsychological composite for trials in early dementia
Helen Brooker, Gareth Williams, Adam Hampshire, et al.
Current Alzheimer Research
|
January 11, 2018
(-)-Phenserine and Inhibiting Pre-Programmed Cell Death: In Pursuit of a Novel Intervention for Alzheimer's Disease
Robert E Becker, Nigel H Greig, Debomoy K Lahiri, et al.
Neurobiology of Aging
|
August 9, 2014
Assessment of ZnT3 and PSD95 protein levels in Lewy body dementias and Alzheimer's disease: association with cognitive impairment
David R Whitfield, Julie Vallortigara, Amani Alghamdi, et al.
Alzheimer'S & Dementia (New York, N. Y.)
|
March 1, 2022
Treatment with glucagon-like peptide-1 receptor agonists and incidence of dementia: Data from pooled double-blind randomized controlled trials and nationwide disease and prescription registers
Caroline Holm Nørgaard, Sarah Friedrich, Charlotte Thim Hansen, et al.
Nature Aging
|
December 19, 2025
Repurposing glucagon-like peptide-1 receptor agonists for the treatment of neurodegenerative disorders
Marwan N Sabbagh, Jeffrey L Cummings, Clive Ballard, et al.
Page
of 48